Payment overview · 2025
General Payments
1 reported records · 1 companies
Healthcare provider profile · identity verified
Allopathic & Osteopathic Physicians|Internal Medicine|Cardiovascular Disease · UNION CITY, TN · NPI 1205884376
Verified facts
CMS Open Payments records show James C Hall, M.D. received $20.59 in general payments during 2025 across 1 reported records.
Esperion Therapeutics, Inc. accounted for 100.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 1 associated product.
These records do not establish that a payment influenced prescribing or medical care.
Payment overview · 2025
1 reported records · 1 companies
Separate record types
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $20.59 | 100.0% | 1 | 2025 |
What were the payments for?
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $20.59 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $20.59 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Felodipine Er | Felodipine | 825 | 195 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 474 | 110 |
| Furosemide | Furosemide | 438 | 112 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 392 | 103 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 389 | 93 |
| Eliquis | Apixaban | 365 | 66 |
| Levothyroxine Sodium | Levothyroxine Sodium | 350 | 95 |
| Sotalol | Sotalol Hcl | 347 | 65 |
| Carvedilol | Carvedilol | 317 | 73 |
| Valsartan | Valsartan | 235 | 56 |
| Atorvastatin Calcium | Atorvastatin Calcium | 234 | 55 |
| Metoprolol Succinate | Metoprolol Succinate | 232 | 69 |
| Potassium Chloride | Potassium Chloride | 202 | 47 |
| Simvastatin | Simvastatin | 188 | 49 |
| Xarelto | Rivaroxaban | 186 | 29 |
| Clopidogrel | Clopidogrel Bisulfate | 162 | 36 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 162 | 43 |
| Amlodipine Besylate | Amlodipine Besylate | 150 | 37 |
| Glimepiride | Glimepiride | 150 | 38 |
| Losartan Potassium | Losartan Potassium | 148 | 36 |
| Gabapentin | Gabapentin | 147 | 32 |
| Jardiance | Empagliflozin | 131 | 20 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 129 | 31 |
| Metformin Hcl | Metformin Hcl | 122 | 34 |
| Prazosin Hcl | Prazosin Hcl | 103 | 21 |
| Entresto | Sacubitril/Valsartan | 98 | 14 |
| Lisinopril | Lisinopril | 98 | 24 |
| Alprazolam | Alprazolam | 94 | 14 |
| Zolpidem Tartrate | Zolpidem Tartrate | 94 | 11 |
| Pantoprazole Sodium | Pantoprazole Sodium | 91 | 21 |
| Omeprazole | Omeprazole | 90 | 23 |
| Nitroglycerin | Nitroglycerin | 86 | 26 |
| Allopurinol | Allopurinol | 78 | 22 |
| Fenofibrate | Fenofibrate,micronized | 77 | 22 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 74 | 19 |
| Ezetimibe | Ezetimibe | 73 | 18 |
| Hydrochlorothiazide | Hydrochlorothiazide | 72 | 14 |
| Diltiazem 24hr Er | Diltiazem Hcl | 66 | 17 |
| Cartia Xt | Diltiazem Hcl | 59 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 59 | 19 |
| Flecainide Acetate | Flecainide Acetate | 58 | 15 |
| Nifedipine Er | Nifedipine | 58 | 13 |
| Tamsulosin Hcl | Tamsulosin Hcl | 57 | 16 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 55 | 17 |
| Buspirone Hcl | Buspirone Hcl | 54 | 11 |
| Benazepril Hcl | Benazepril Hcl | 53 | 14 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 52 | 14 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 52 | 14 |
| Meloxicam | Meloxicam | 52 | 12 |
| Lovastatin | Lovastatin | 47 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 46 | 18 |
| Amiodarone Hcl | Amiodarone Hcl | 40 | 13 |
| Azithromycin | Azithromycin | 39 | 35 |
| Metoprolol Tartrate | Metoprolol Tartrate | 38 | 11 |
| Cilostazol | Cilostazol | 36 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 35 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 34 | suppressed |
| Synthroid | Levothyroxine Sodium | 33 | suppressed |
| Celecoxib | Celecoxib | 31 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 30 | suppressed |
| Minoxidil | Minoxidil | 30 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 29 | suppressed |
| Metolazone | Metolazone | 29 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 28 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 28 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 28 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 27 | suppressed |
| Ondansetron Odt | Ondansetron | 26 | suppressed |
| Trulicity | Dulaglutide | 26 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 24 | suppressed |
| Temazepam | Temazepam | 24 | suppressed |
| Torsemide | Torsemide | 24 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 23 | suppressed |
| Glipizide Er | Glipizide | 23 | suppressed |
| Spironolactone | Spironolactone | 23 | suppressed |
| Baclofen | Baclofen | 22 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 22 | suppressed |
| Lorazepam | Lorazepam | 22 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 21 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 21 | suppressed |
| Multaq | Dronedarone Hcl | 21 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 19 | suppressed |
| Estradiol | Estradiol | 19 | suppressed |
| Glipizide | Glipizide | 19 | suppressed |
| Ozempic | Semaglutide | 19 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 18 | suppressed |
| Fenofibrate | Fenofibrate | 18 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 18 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 18 | suppressed |
| Verapamil Er | Verapamil Hcl | 18 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 17 | suppressed |
| Januvia | Sitagliptin Phosphate | 17 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 17 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 17 | 16 |
| Famotidine | Famotidine | 16 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 16 | suppressed |
| Digoxin | Digoxin | 15 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 15 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 14 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 13 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 13 | suppressed |
| Betaxolol Hcl | Betaxolol Hcl | 13 | suppressed |
| Lansoprazole | Lansoprazole | 13 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 13 | suppressed |
| Ropinirole Er | Ropinirole Hcl | 13 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 13 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 13 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 12 | suppressed |
| Clonazepam | Clonazepam | 12 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 12 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Ibuprofen | Ibuprofen | 12 | suppressed |
| Ranolazine Er | Ranolazine | 12 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 11 | suppressed |
| Amoxicillin | Amoxicillin | 11 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 11 | suppressed |
| Methylprednisolone | Methylprednisolone | 11 | suppressed |
| Pentoxifylline | Pentoxifylline | 11 | suppressed |
| Prednisone | Prednisone | 11 | suppressed |
| Rybelsus | Semaglutide | 11 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 11 | suppressed |
Timeline
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $20.59 · 1 records | Esperion Therapeutics, Inc. | NEXLETOL | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error